News Archive

Press release


6 April 2004

Dishman has achieved ISO 14001 and OHSAS 18001 certification of BVQI Switzerland


Dishman to expand operations in India and China


21 January 2009

(AHMEDABAD, INDIA), January 21, 2009 – Dishman Group of Ahmedabad, India, has announced capital investments of more than $33 million; $20 million in the current financial year and $13 million planned for fiscal year 2009 which begins in April. The global pharmaceutical services provider will see significant expansion of its capabilities and offerings this year, with the addition of a high-potency facility near Dishman’s headquarters in the district of Ahmedabad and a new plant in Shanghai, China.

The facility in India is a state-of-the-art, 4,300-square-meter plant catering to cytotoxic and non-cytotoxic highly active substances and one of the largest and most flexible custom-manufacturing high-potency facilities in the world. In Bavla, the plant will be managed and operated by Dishman subsidiary, Switzerland-based CARBOGEN AMCIS AG, and is scheduled to be operational mid-2009.

The facility in Shanghai will include a production plant, a warehouse, its own dedicated on-site utilities and administrative/quality control offices. Construction of the facility is fully underway and is expected to be fully staffed and operational by the second quarter of 2009.
“The new facilities in India and China will enable customers to solely collaborate with Dishman as a technical partner from early stage route development to market supply, without volume limitations. The addition of the plant in India offers customers a seamless approach to high-potency research and development, process optimization and commercial manufacturing,” said Jay Vyas, managing director of Dishman.
Dishman places a focus on safety and security, with an emphasis risk management strategy, which provides redundancy of supply in multiple Asian sites and countries and also provides ease of Asian collaboration. “Additional locations and infrastructure provide secure options that maximize speed, flexibility and cost advantages for customers with the same safety and quality standards globally,” said Vyas.

Facility to manufacture Cancer drugs and other high potency drugs


12 August 2008

Dishman is building Asia's largest facility to manufacture Cancer drugs and other high potency drugs at its Bavla plant. This facility is designed and being commissioned by its daughter company CARBOGEN AMCIS AG (CA) who has expertise in this area. Facility will be operated by CA's Swiss team and it will produce API's for CARBOGEN AMCIS AG to offer to its customers. Company has spent 50 crore rupees in building this facility.


Dishman is venturing in to manufacturing and marketing of disinfectant


9 August 2008

Dishman is venturing in to manufacturing and marketing of disinfectant and sanitization products in India, Saudi Arabia and Australia. Company will make formulated products for hospitals, domestic use and industrial disinfection. In India and Australia, this will be done by company and its Australian subsidiary where as in Saudi, this will be under a JV called Dishman Arabia Ltd. with a Saudi partner. Company expect to reach 100 crore sales in 3 years from this new division.


Dishman is building Asia’s largest facility


19 July 2008

Dishman is building Asia’s largest facility to manufacture Cancer drugs and other high potency drugs at its Bavla plant. This facility is designed and being commissioned by its daughter company CARBOGEN AMCIS AG (CA) who has expertise in this area. Facility will be operated by CA’s Swiss team and it will product APIs for CARBOGEN AMICS AG to offer to its customers. Company has spent 50 crore rupees in building this facility.


Dishman Cholesterol and Lanoline products is sited in Veenendaal


2 June 2008

The current production of Dishman Cholesterol and Lanoline products is sited in Veenendaal, a city in the centre of the Netherlands. Today, the supply of Vitamin D and Vitamin D analogues is still sited at the area of Solvay Pharmaceuticals. However, Dishman has recently decided to build a brand new facility for the Vitamin D Analogues in Veenendaal. The new facility will not only allow the production of the present Vitamin D Analogues, but also the development of new high potent products up to 1kg. This facility is expected to be ready in the course of 2009. From that moment the supply of Vitamin D and the Vitamin D Analogues will be concentrated in Veenendaal.

Inauguration of Unit 8 at Bavla Plant


9 February 2008

Inauguration of Unit 8 at Bavla Plant. This unit was inaugurated by Mr Jay R. Vyas and Mr Francisco Junyet (Solvay Pharmaceuticals) last 27 February 2008. This new facility has 4 floors dedicated to multi-products. See pictures of the inauguration.


Dishman acquires fine chemicals


19 November 2007

Dishman acquires the fine chemicals, vitamin D and Vitamin D analogues business from Solvay.


Press Release


23 July 2007

Dishman Pharmaceuticals and Chemicals Ltd (DPCL) announces that it has signed a Memorandum of Understanding (MoU) with Solvay Pharmaceuticals BV (Solvay), the Netherlands to acquire the fine chemicals, vitamin D and vitamin D analogues business from Solvay for an undisclosed amount. Read Press Release.


Dishman acquired IO3S


8 January 2006

Dishman acquired IO3S of Bern Switzerland through its wholly owned subsidiary Dishman Switzerland Ltd. IO3S is the only company in the world in the field of consultancy and research in Ozone Chemistry. It has a fully developed laboratory as well as a pilot plant for Ozone based reactions. IO3S has created a strong IP, having serviced major global pharma companies and specialty chemical companies.


Dishman’s manufacturing site in Bavla, has been granted the International Safety Award


11 April 2005

Dishman’s manufacturing site in Bavla, India, has been granted the International Safety Award by the British Safety Council due to outstanding achievements w.r.t. its SHE Management System.


Dishman signed a co-operation & joint API development agreement with Polpha


1 March 2009

DISHMAN SIGNED A CO-OPERATION & JOINT API DEVELOPMENT AGREEMENT WITH POLPHARMA - POLAND

Dishman Pharma - India and Polpharma - Poland have signed a cooperation and joint API development agreement. Polpharma is in particularly a strong player in its home market and a leader in the Central and Eastern European markets and CIS countries with a turnover of ca 400 million US dollars. Polpharma is also a CEE leader in the API sales with almost 90% of which in regulated markets including USA. Dishman group, a dedicated CRM player has ca. 200 million US dollars turnover. Both companies feel that this partnership will benefit mutually and pave the way for a stronger growth in coming years.

Theo Iliopoulos, Polpharma VP Operations and General Manager Fine Chemical said:

“As the Development and Manufacturing model changes and the Regulatory requirements become ever stricter it is crucial for Development and Manufacturing to adjust and build partnerships and networks with other groups. It will allow us to come up with solutions to meet the market expectations and sustain the increased competition between major pharmas and generic pharmas and solve different problems”. “This is the unprecedented power of doing things together" he argued, “it is the future of the pharmaceutical industry”. “Looking for such partnerships with academic centers, service providers with innovative technologies and development laboratories of proven efficiency is the way forward for an industry facing fierce competition”.

J R Vyas, Managing Director of Dishman said:

"Dishman has now strategies to cooperate with leading API players and pharma companies such as Polpharma with their strength in R&D and API plants in India as CRAM player. Such partnerships will ensure long term API manufacturing contracts to Dishman and also provide API development and DMF preparation capabilities to partners to cut short their time to market."

Dishman Europe Ltd receives the Queens Award


17 April 2004

Dishman Europe Ltd receives the Queens Award for enterprise “International Trade”, one of Britain’s most prestigious awards for British companies


CEO Mark Griffiths Appointed to Dishman Board of Directors


3 October 2014

Mark C. Griffiths, global chief executive officer of Dishman and CARBOGEN AMCIS, has joined the board of directors of Dishman Pharmaceuticals and Chemicals Ltd.

The appointment was made public by Shri Arpit J. Vyas, managing director, Dishman Pharmaceuticals and Chemicals Ltd. "We are excited to welcome Mark to the board of Dishman. Mark's leadership at the helm of CARBOGEN AMCIS has turned the company into a success story in the pharmaceutical industry, leading to an increase in business from 63 to 100 million CHF since his appointment. We look forward to a path of continued success together," said Vyas. Griffiths has served as chief executive officer since 2011 and has been associated with CARBOGEN AMCIS as director of operations and chief executive officer for almost ten years. He also worked for the Dishman Group as operations advisor overseeing the design and construction of the group's large-scale manufacturing facilities for commercial supply of Highly Potent APIs (HPAPIs) in Shanghai, China, and Ahmedabad, India.

Griffiths has over 31 years of relevant industrial experience delivering high added value technical and operational solutions within the pharmaceutical and fine chemical industry. Qualified as an engineer and having gained significant experience in the management of complex, multi-task, multi-input projects, he brings a cross-functional ability to anticipate and optimize technical, operational and management issues. Griffiths has designed, built and managed facilities ranging in function from research and development to manufacturing. Griffiths holds a Master of Science in engineering from Bristol University, UK.

Dishman is a leading global outsourcing partner for the pharmaceutical industry, offering a rich portfolio of development, scale-up and manufacturing services that straddle the entire pharmaceutical value chain. The company offers cost-effective, high-quality research, development and manufacturing services that include production and supply of tailor-made, high-quality Intermediates and generic APIs to the global pharmaceutical industry. Its global presence includes multiple manufacturing sites in Europe, India, and China - making it one of the most geographically diversified players in the industry. The Dishman board of directors consists of Shri Janmejay R. Vyas, Chairman & Managing Director; Mrs. Deohooti J. Vyas, Whole-Time Director; Shri Arpit J. Vyas, Managing Director; Shri Yagneshkumar B. Desai, Director; Shri Sanjay S. Majmudar, Director; and Shri Ashok C. Gandhi, Director.

IPO 40 times oversubscribed


3 April 2004

IPO 40 times oversubscribed. 25% of stock are issued on the Mumbai Stock Exchange.


New high tech laboratory for Dishman Netherlands

Strong commitment of Dishman
27 November 2009

Strong commitment of Dishman to new Vitamin D analogs & HiPo APIs

The new high containment cGMP laboratory of Dishman Netherlands was opened formally on November 27th by Mr. Jay Vyas, Chairman and owner of the Indian Dishman Group.

Important attendees include the Serbian ambassador Mr. Cedomir Radojkovic, and different representatives from such multinationals as Pfizer and Solvay.

This project was realized with the support of several companies:  Van Spanje, Techtron, Cleangrad, de Van Looy Group, Termovent and Waldner Benelux. 

Dishman Netherlands has accomplished the construction and validation of a full cGMP production laboratory for APIs in Veenendaal, The Netherlands. The laboratory consists of 6 dedicated clean rooms with a scale of operation of up to 1 kg in addition to all standard laboratory facilities. FDA compliance audit is expected in H1 of 2010.

The decision to build this production laboratory is part of Dishman’s strategy to develop new Vitamin D analogues and high potential API’s to complement the current product portfolio.  Furthermore, to develop business opportunities with new business partners:  for contract research, product development and contract manufacturing.  

Dishman Netherlands currently offers vitamin D analogues such as alfacalcidol, calcifediol, calcitriol, & dihydrotachysterol-2. Our other products include Vitamin D3 and D2; cholesterol and lanolin alcohols. Vitamin D and vitamin D analogs are used in the food, feed and pharmaceuticals industries. Vitamin D analogues are used in the combat against Psoriases, Osteoporosis and rickets. Cholesterol is used in diverse applications such as drug delivery systems, cosmetics, animal nutrition (Shrimps) and liquid crystals.  Lanolin oils are used in cosmetics (Dusoran) and also for the treatment of leather.

The opening of this laboratory in the midst of an economic recession is a sign of the strong commitment which the Dishman Group has to its Dutch subsidiary. 

# # #

More information can be found at www.dishman-netherlands.com

# # #

Profile

Dishman Netherlands (www.dishman-netherlands.com) location in Veenendaal was founded in 1946. It was taken over by the Indian Dishman Group from the Belgian company Solvay pharmaceuticals in November 2007.

Dishman Group (www.dishmanGroup.com) is headquartered in Ahmedabad, India and is listed on the Bombay Stock Exchange (BSE). In 2008/09, Dishman had sales of over US$230m. Dishman Group is a global outsourcing partner for the pharmaceutical industry offering a portfolio of development, scale-up and manufacturing services.

The products and services offered span customers’ needs from chemical development to commercial manufacture and supply of active pharmaceutical ingredients.

 

Dishman appoints Chris Oates as Chief Operating Officer


4 January 2010

New Role Will Oversee Dishman Indian and Chinese Facilities

 

Dishman Group of Ahmedabad, India, a leading products and services provider to the pharmaceutical industry, has announced the appointment of Chris Oates to the position of Chief Operating Officer. Oates will report to Nick Green, President of the Dishman global contract research and manufacturing services (CRAMS) business.

 

Oates will assume responsibility for Indian and Chinese operations within the company. He will be managing the development, operation, and improvement of the systems in the two manufacturing sites in India (Bavla and Naroda) and the new Shanghai facility which is due for completion mid-2010. In addition to the units in Naroda and China, Oates will be responsible for the 9 operating units at Bavla, including a large scale high potency facility which will be inaugurated at the end of January. The new state-of-the-art high potency facility will extend CARBOGEN AMCIS’ manufacturing capacity to multi-tonne scale and will be the first of its kind to be located in Asia.

 

Oates’ experience combines both production and operational roles in the contract manufacturing arena. He will play a pivotal role in expanding the company’s core CRAMS business.

 

Oates holds a bachelor’s degree in applied chemistry from the University of Huddersfield in the UK. His expertise is built on more than 20 years working within the pharmaceutical industry. He most recently served as Managing Director of Uquifa Mexico. His previous experience includes 6 years at Avecia Pharmaceuticals in the UK where he held the position of Operations Manager and as the position of Senior Production Manager for Syngenta (Agrochemicals).

 

“I am looking forward to taking up this new challenge and am very excited by what I believe will be a very successful future for the company” said Oates. “Dishman can provide the full continuum of services, from process R&D to large-scale commercial manufacturing, in multiple locations around the globe. The company is ideally placed to build upon its success to date and become the industry leading CRAMS partner.”

 

CARBOGEN AMCIS AG Opens New High-Potency Manufacturing Unit

in Ahmedabad, India
27 January 2010

BUBENDORF, Switzerland (Jan. 27, 2010) — CARBOGEN AMCIS AG today inaugurated its new High-Potency Active Pharmaceutical Ingredient (API) facility. Located on the site of its parent company, Dishman Pharmaceuticals and Chemicals Ltd., in Ahmedabad, India, the new facility is the first of its kind to be opened in India, and one of only a few such facilities worldwide.

 

 

The inaugural event, hosted on Jan. 27, 2010, was attended by 200 people, including customers, staff and members of the local business community. The facility was opened with the help of Dr. Nigel Courtenay-Luck, a leading oncology researcher, co-founder of Antisoma, senior lecturer at Hammersmith Hospital, London, and founder of Saturn Biosciences.

 

The facility’s large-scale capacity (currently up to 1,600 L) will be capable of producing multi-tonne quantities of highly potent APIs (down to < 1 µg/m3 OEL). It is expected that most of the products will be in support of the growing demand for large volume oncology products, although there has been considerable interest in cardiovascular and central nervous system-related production.

 

“Combining CARBOGEN AMCIS’ experience in the High-Potency area with the established infrastructure and support systems on the Dishman Bavla site make this a truly unique offering for customers,” said Jay Vyas, managing director, Dishman Pharmaceuticals and Chemicals Ltd.

 

“This is a very exciting time for us,” said Charlie Johnson, High-Potency business manager for CARBOGEN AMCIS. “We are now able to offer customers first-class, engineering-controlled, Highly Potent API production across two continents. CARBOGEN AMCIS’ customers will benefit from economies of scale as their API demands grow. We also will be able to offer competitive production of API to support life-cycle management.”

 

The new facility extends the capacity of CARBOGEN AMCIS’ existing High-Potency API facilities in Bubendorf, Switzerland.

Strategic alliance with Codexis


17 February 2010

Customers will benefit from cheaper, cleaner and greener processes

(AHMEDABAD, INDIA), February 17, 2010 – Today, the Dishman Group announced the formation of a strategic alliance with Codexis, Inc. a California based biotechnology company.  This strategic partnership covers the use of Codexis’ proprietary enzymatic biocatalysis technology for the manufacture of building blocks, intermediates and APIs for innovator pharmaceutical companies.  Dishman will be a preferred contract manufacturer for Codexis and will be able to offer the technology to its own customers.  In addition, the companies will work exclusively on certain select accounts. 

 

Codexis offers a wide selection of enzymes for the pharmaceutical synthesis of chiral compounds. With the majority of today’s drugs containing at least one chiral centre, this technology is directed at the very heart of pharmaceutical manufacture.  In comparison to traditional chemical synthesis, this technology offers a number of significant advantages: cost reduction compared with conventional complex transformations as a result of telescoped processes, increased specificity gives improved yields and often improved impurity profiles, significant reduction in environmental impact through reduce use of organic solvents and reduced energy processes.

 

This alliance will benefit Codexis and its customers by enabling Codexis to offer production of both intermediates and final APIs in Dishman’s world-class manufacturing asset base.  “We are delighted to be working with Codexis on this innovative technology.  It adds another dimension to the already extensive portfolio of services offered by the Dishman Group.  Our customers will benefit from cheaper, cleaner, greener processes manufactured in a low cost environment, a significant differentiator given today’s regulatory and market conditions ” said Nick Green, President Dishman CRAMS.

Appointment of Group CEO


6 March 2013

Dishman today announced that Mark C. Griffiths has been named Chief Executive Officer of Dishman Group, effective today. In his new role, Griffiths will work closely with Arpit Vyas, the Group MD and will report to Jay Vyas, Dishman Group Chairman. Mark C. Griffiths has been associated with Dishman Group for almost ten years, most recently as CEO of the Swiss subsidiary Carbogen Amcis. Griffiths has over 28 years of relevant industrial experience delivering high added value technical and operational solutions within the pharmaceutical and fine chemical industry. Qualified as an engineer and having gained significant experience in the management of complex, multi-task, multi-input projects, he brings a cross-functional ability to anticipate and optimize technical, operational and management issues. Griffiths has designed, built and managed facilities ranging in function from research and development to manufacturing. Griffiths holds a Master of Science in engineering from Bristol University, UK.

Appointment of Group CEO


3 June 2013

Dishman today announced that Mark C. Griffiths has been named Chief Executive Officer of Dishman Group, effective today. In his new role, Griffiths will work closely with Arpit Vyas, the Group MD and will report to Jay Vyas, Dishman Group Chairman. Mark C. Griffiths has been associated with Dishman Group for almost ten years, most recently as CEO of the Swiss subsidiary Carbogen Amcis. Griffiths has over 28 years of relevant industrial experience delivering high added value technical and operational solutions within the pharmaceutical and fine chemical industry. Qualified as an engineer and having gained significant experience in the management of complex, multi-task, multi-input projects, he brings a cross-functional ability to anticipate and optimize technical, operational and management issues. Griffiths has designed, built and managed facilities ranging in function from research and development to manufacturing. Griffiths holds a Master of Science in engineering from Bristol University, UK.

Clarification on reports in the media on the sale of the Shanghai plant


10 March 2014

With reference to the news item appearing in the financial and chemical press regarding “Sale of Company’s Shanghai Plant”, Dishman Pharmaceuticals and Chemicals Ltd has clarified there is no truth in the said news. This information was not given to the media by any of the Company’s officials & the Company also does not envisage Sale of the China facility. Indeed we are currently running the plant and have identified a number of additional projects to increase revenues from the plant in Shanghai. The Shanghai plant is an integral part of the Dishman strategy on the production of Highly Potent API, being capable of running production of Category III oncology products at scales of up to 8,000L.

Appointment of Global Chief Financial Officer


1 April 2014

Dishman Pharmaceuticals and Chemicals Ltd is pleased to announce that Mr. Rajashekhar Bhat has been appointed as a Global Chief Financial Officer ("CFO") of the Dishman Group of Companies with effect from April 01, 2014. Mr Rajashekhar Bhat holds an MBA in Finance from the Indian Institute of Management, Ahmedabad and B. Eng in Mechanical Engineering from Mumbai University. He has more than 25 years of experience in the fields of banking and corporate financial strategy.


Dishman Continues to Invest in Expanding High Potency Capabilities


14 April 2014

To meet rising demand for highly potent active pharmaceutical ingredients spurred by the growing targeted therapy approach in the treatment of diseases, in particular oncology, Dishman today announced that it has initiated a capital investment project to upgrade its high potency capabilities. The investment will be a new Class 100,000 High Potency Kilo-lab with 110-sqm of floor space at its large-scale commercial facility for highly potent APIs in Bavla, India. The Kilo-lab features multiple glass-lined and stainless steel reactors and agitated nutsche filter driers equipped with charging/discharging isolators. A negative pressure cascade and the high-efficiency particulate air filters allow the safe production of highly potent APIs at exposure limit values between 1 μg/m³ and 50 ng/m³ at 8-hour time weighted average. Thanks to its state-of-the-art R&D and manufacturing infrastructure and expertise in high potency API Dishman Group is well positioned to significantly contribute to the development of next-generation cancer treatments.

Dishman to undertake new dedicated cGMP /US-FDA compliant facilities


27 January 2005

Dishman offers to undertake to fully fund new dedicated cGMP /US-FDA compliant facilities for individual clients where projects have an annual value of at least 5 Mio. USD and a contract period of at least 3 years.


News

11 August 2016
Dishman Celebrates a Decade of Success Since Acquisition of CARBOGEN AMCIS

2 February 2016
Dishman Netherlands awarded for its Corporate Social Responsibility.

24 September 2015
Dishman has been awarded manufacture of SIRTURO® (bedaquiline) API

9 February 2015
Successful FDA inspection at the Netherlands Dishman site

VIEW NEWS ARCHIVE